Yi Hong Yao
Chief Tech/Sci/R&D Officer en CELLULAR BIOMEDICINE GROUP, INC. .
Perfil
Yi Hong Yao is currently the Chief Scientific Officer at AbelZeta Pharma, Inc. Prior to this, he worked as a Director at Medimmune, Inc. from 2011 to 2015.
Dr. Yao received his graduate degree from Boston University, his doctorate from the University of Kansas, and his undergraduate degree from Fudan University.
Cargos activos de Yi Hong Yao
| Empresas | Cargo | Inicio |
|---|---|---|
| CELLULAR BIOMEDICINE GROUP, INC. | Chief Tech/Sci/R&D Officer | 01/08/2015 |
Antiguos cargos conocidos de Yi Hong Yao.
| Empresas | Cargo | Fin |
|---|---|---|
| Medimmune, Inc. | Director/Board Member | 01/07/2015 |
Formación de Yi Hong Yao.
| Boston University | Graduate Degree |
| University of Kansas | Doctorate Degree |
| Fudan University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
AbelZeta Pharma, Inc.
 AbelZeta Pharma, Inc. BiotechnologyHealth Technology Cellular Biomedicine Group, Inc. is a holding company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. It specializes in immune cell therapy. The company was founded in 2009 and is headquartered in Rockville, MD. | Health Technology |
| Medimmune, Inc. | Health Technology |
- Bolsa de valores
- Insiders
- Yi Hong Yao
